05 Jun Novo Nordisk and Eli Lillys GLP-1s investment case just became even more compelling As published in FA News on 30 May 2024 By Philip Short Flagship Asset Management fund manager The investment case for Novo Nordisk and Eli Lilly became even more compelling last week after a study found that the fast-selling weight loss GLP-1 drug semaglutide, sold as Ozempic and Wegovy, helps protect the kidney function of overweight or heart disease patients
For example, when we had a question that a staff member over the phone was unsure about, they got back to us via email the next day with an answer
While Glutathione is often discussed in the context of general wellness, its specific benefits for men's skin care are significant and worth exploring
10.3390/life11080732 Life 137 NishiwakiH.ItoM.IshidaT.HamaguchiT.MaedaT.KashiharaK.et al (2020)
Higher protein, which balances protein across your meals to help control your appetite
Current Recommendations GLP-1 medications are not recommended during breastfeeding
